Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb study of guselkumab and golimumab combination induction and maintenance therapy in moderate to severe active Crohn's disease
CTR20222703Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of guselkumab, golimumab, guselkumab + golimumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Started Apr 2023; status: active.
02
Drugs
guselkumabgolimumabguselkumab + golimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on CTR20222703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222703.